Literature DB >> 1875014

Ultrasonic and endocrinologic aspects in gonadotropin releasing hormone induction of ovulation.

D Mango1, S Ricci, P Manna, L Olleja, R Tripodi, G Tropeano, A Lucisano.   

Abstract

Ovarian growth, follicular size, 17 beta-estradiol (E2), androstenedione (A) and testosterone (T) peripheral levels were evaluated in 12 hypogonadotropic patients during the follicular phase on 12 cycles of pulsatile GnRH iv administration. During GnRH therapy, significant correlations between E2 plasma levels and volume of the dominant follicle (p less than 0.001) as well as total follicular volume (p less than 0.001) and total ovarian volume (p less than 0.01) were found. Plasma A was significantly related to the ultrasonic changes of ovarian stroma and those follicles which usually fail to ovulate. Plasma T showed a significant correlation with ovarian stroma (p less than 0.05). Significant correlations of E2/A and E2/T peripheral ratios with volume of the dominant follicle (p less than 0.01) were also found. In spontaneous ovulatory cycles, similar correlations between endocrine and morphological parameters have been already published. The findings of the present investigation indicate that in spontaneous and GnRH-induced cycles the endocrine events associated to the follicular development are quite similar. In hypogonadotropic patients, a "normal" follicular maturation may be obtained by means of this therapy.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1875014     DOI: 10.1007/BF03349084

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  16 in total

1.  Correlation of serum estradiol levels and ultrasound monitoring to assess follicular maturation.

Authors:  M E Hull; K S Moghissi; D M Magyar; M F Hayes; I Zador; J M Olson
Journal:  Fertil Steril       Date:  1986-07       Impact factor: 7.329

2.  Blood production and ovarian secretion rates of estradiol-17 beta and estrone in women throughout the menstrual cycle.

Authors:  D T Baird; I S Fraser
Journal:  J Clin Endocrinol Metab       Date:  1974-06       Impact factor: 5.958

Review 3.  Ovulation induction with gonadotropin-releasing hormone.

Authors:  H A Zacur
Journal:  Fertil Steril       Date:  1985-10       Impact factor: 7.329

4.  Pulsatile low dose luteinizing hormone-releasing hormone treatment for induction of follicular maturation and ovulation in women with amenorrhoea.

Authors:  G Skarin; S J Nillius; L Wide
Journal:  Acta Endocrinol (Copenh)       Date:  1982-09

5.  Correlation of inhibin and follicle regulatory protein activities with follicular fluid steroid levels in anovulatory patients.

Authors:  G S diZerega; R P Marrs; R Lobo; E L Ujita; J Brown; J D Campeau
Journal:  Fertil Steril       Date:  1984-06       Impact factor: 7.329

6.  Pulsatile administration of Gn-RH in hypothalamic amenorrhea.

Authors:  G Leyendecker; L Wildt
Journal:  Ups J Med Sci       Date:  1984       Impact factor: 2.384

7.  Correlation of ultrasonic measurement of ovarian follicle size and serum estradiol levels in ovulatory patients following clomiphene citrate for in vitro fertilization.

Authors:  J M Vargyas; R P Marrs; O A Kletzky; D R Mishell
Journal:  Am J Obstet Gynecol       Date:  1982-11-01       Impact factor: 8.661

8.  Concentration of oestrogens and androgens in human ovarian venous plasma and follicular fluid throughout the menstrual cycle.

Authors:  K P McNatty; D T Baird; A Bolton; P Chambers; C S Corker; H McLean
Journal:  J Endocrinol       Date:  1976-10       Impact factor: 4.286

9.  Inhibin production by bovine ovarian tissues in vitro and its regulation by androgens.

Authors:  K M Henderson; P Franchimont
Journal:  J Reprod Fertil       Date:  1983-03

10.  Pregnancies following chronic intermittent (pulsatile) administration of Gn-RH by means of a portable pump ("Zyklomat")--a new approach to the treatment of infertility in hypothalamic amenorrhea.

Authors:  G Leyendecker; L Wildt; M Hansmann
Journal:  J Clin Endocrinol Metab       Date:  1980-11       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.